HIGHLIGHTS
- who: Waleed Kian from the (IRCCS), Italy University of Naples Federico II, Italy have published the paper: Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer, in the Journal: (JOURNAL)
- what: Mobocertinib is a novel drug with limited efficacy for pretreated EGFRex20ins-positive NSCLC, which however is clearly better than that of alternative options, like EGFR inhibitors or docetaxel.
- how: The efficacy results are presented in Figure 1.
SUMMARY
Epidermal growth factor receptor (EGFR) is an oncogenic transmembrane protein that upon activation by . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.